- Home
- MAC vs CNTA Comparison
MAC vs CNTA Comparison
Compare MAC & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAC | CNTA |
|---|---|---|
| Founded | 1964 | 2020 |
| Country | United States | United Kingdom |
| Employees | 2845 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.1B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MAC | CNTA |
|---|---|---|
| Price | $23.61 | $40.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | $20.50 | ★ $43.17 |
| AVG Volume (30 Days) | ★ 3.0M | 1.5M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | 11.36 | ★ 29.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,013,983,000.00 | $15,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.80 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.43 | N/A |
| 52 Week Low | $15.94 | $12.78 |
| 52 Week High | $25.72 | $40.26 |
Technical Indicators
Market Signals| Indicator | MAC | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 69.06 |
| Support Level | $17.84 | $39.58 |
| Resistance Level | N/A | $40.26 |
| Average True Range (ATR) | 0.65 | 0.18 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 41.23 | 85.71 |
Price Performance
Historical ComparisonAbout MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 27 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with a power center and seven other real estate assets. The company's total portfolio has 39.9 million square feet of gross leasable area and averaged $867 sales per square foot over the 12 months ended in September 2025.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.